Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Senate Health Cmte. Health Counsel Lehman Moving To Bush Administration

Executive Summary

The Senate Health Committee staff will have a new point person for healthcare issues following the departure of health counsel Dirksen Lehman, who is joining the Bush Administration.

You may also be interested in...

Rx Reimportation Push Resumes: Gutknecht Sees Open Borders As Inevitable

Personal importation of prescription drugs will inevitably lead to reimportation at the wholesale level, Rep. Gutknecht (R-Minn.) suggested at a Washington, D.C., press conference Jan. 31.

Medicare Rx Debate To Be Reopened In House Ways & Means/Health Cmte

The House Ways & Means/Health Subcommittee will reopen the debate on how to provide a prescription drug benefit to Medicare beneficiaries, Chairman Johnson (R-Conn.) said after being named to head the subcommittee Jan. 5.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts